Dave Fornell, DAIC Editor

Dave Fornell, Editor DAIC

Blog | Dave Fornell, DAIC Editor | March 16, 2016

The Eve of a Paradigm Shift in Cardiology?

While there are constant advances in cardiac technologies, it is rare when one of these new ideas may rapidly challenge the standard of care in a very short period of time. However, that is exactly what has happened with the introduction of transcatheter aortic valve replacement (TAVR). In a few short years since the U.S. Food and Drug Administration’s (FDA) market clearance of the Edwards Lifesciences’ Sapien valve in 2011 and Medtronic’s CoreValve in 2012, both these devices have shown vast improvements in survival for very sick, inoperable patients. Results were also outstanding for extreme-risk and high-risk surgical patients. The CoreValve has data showing it outperforms surgical repair in patient outcomes. This has made many experts wonder if there will soon be a paradigm shift in care, when the question switches from which patients qualify for TAVR, to which patients would actually benefit from open-heart surgical aortic valve replacement (SAVR) over TAVR.

That great question has been limited up until now for very sick patients, but both devices are about to start FDA investigational device exemption (IDE) studies in 2016 to see if low-risk surgical patients fare better with TAVR than SAVR. These two trials will undoubtedly be the next blockbuster, late-breaking studies that cardiologists will be waiting on the edge of their seats for.  This is the cardiology equivalent of a Hollywood blockbuster movie where fans camp in front of the theaters for days waiting to be the first in line to see the premier.

The FDA approved expanded indication trials for low-risk surgical patients using the Sapien 3 device in January and CoreValve Evolut R in February. Patients with aortic stenosis, who are at a low surgical mortality risk as determined by a heart team, will be enrolled in these trials.

If these trials show TAVR outcomes are at least equal to SAVR, open-heart valve surgery will likely see a rapid demise in the coming years. However, the final nail in the coffin for SAVR will only come after long-term follow-up. That data is needed to show the durability of TAVR valves over many years.

Come by and say “hello” to me at future TCT and ACC meetings when those presentations occur.  You will find me camped out the night before in front of the doors to the main arena so I have a front row seat at the premier.

For more details on the shift in care toward  TAVR, watch my video interview with Michael Reardon, M.D., about  TAVR having better outcomes than SAVR at http://bit.ly/1n6OvHe.

Watch the VIDEO “How to Build An Integrated Heart Team.” Brijeshwar Maini, M.D., and Brian Bethea, M.D., from Tenet Florida’s structural heart program, explain the importance of building a good heart team and how that team should interact. 

Related Content

Montreal Heart Institute Performs First Robotic Mitral Valve Surgery
News | Robotic Systems| September 22, 2017
The Montreal Heart Institute (MHI) announced the acquisition of the da Vinci Xi, a new-generation surgical robot, and...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Overlay Init